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Summary 4-Hydroxyandrostenedione (4-OHA) was administered (250 mg intramuscularly 2-weekly) in a
phase 2 clinical trial to 20 postmenopausal patients with advanced breast cancer, who had failed other
endocrine therapy. Seven out of 18 assessable patients (39%) responded with minimal toxicity. Endocrine
studies demonstrated that the drug produced significant initial falls in oestradiol and oestrone levels, but that
these levels rose toward pretreatment levels as the study progressed. Sex hormone binding globulin (SHBG)
levels gradually fell during the study suggesting that the drug has a minor degree of androgenic activity albeit
of no clinical significance. There was a transient reduction of adrenal steroid levels, which remained however
within the normal range. There were no symptoms of adrenal insufficiency.
4-Hydroxyandrostenedione (4-OHA), a derivative of andro-
stenedione, has been shown to have significant therapeutic
activity as a second-line hormonal treatment in advanced
breast cancer (Coombes et al., 1987).
Following parenteral administration, reductions in oest-
radiol concentration to 20-40% of pretreatment levels are
seen, and response rates of 33-36% have been reported
(Combes et al., 1987), which are similar to those seen with
other second-line hormones in comparable patients (Smith et
al., 1982).
The oestrogen-lowering activity of 4-OHA is due to
aromatase inhibition, blocking conversion of andro-
stenedione to oestrone and testosterone to oestradiol, which
takes place in adipose tissue and muscle in post-menopausal
or oophorectomized women (Brodie et al., 1987). Unlike
aminoglutethimide (AG), there is not thought to be an effect
upon adrenal steroidogenesis (Coombes et al., 1984), and
adrenal insufficiency has not been reported.
We report the clinical and endrocrine effects of 4-OHA in
post-menopausal women with advanced breast cancer.
Patients and methods
Patients
Patients who were post-menopausal for at least one year, or
who had had a previous bilateral oophorectomy with a histo-
logically proven diagnosis of breast cancer and confirmed
recurrence were eligible for study. All patients had failed at
least one previous endocrine manoeuvre. Their demographic
variables are shown in Table I. The mean age was 65 years
(range 46-85).
Other entry requirements were: objective evidence of
evaluable progressive disease, no previous treatment with
AG, a WHO performance status of 0-2, a life expectancy
greater than 3 months. Informed consent was obtained from
all patients and approval was given by the local Ethical
Review Committee. No patients had received endocrine or
chemotherapy in the 4 weeks prior to study.
4-OHA
4-OHA (CGP 32349) was supplied in 250 mg vials by Ciba
Geigy Pharmaceuticals as a sterile microcrystalline powder,
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and was made up in 2 ml normal saline immediately prior to
use. It was administered by deep i.m. injection at a dose of
250 mg into the buttocks (alternating) every 2 weeks.
Biochemistry
Specific endocrine measurements were made from serum
taken at weeks 0, 1, 2, 8 and 16; these were in addition to
other routine clinical chemistry investigations. The ER status
was not routinely measured. Patients were always seen at the
same time on each hospital visit, and for all patients this was
between 10:00 and 12:00.
Analysis of serum oestrone was by isotope dilution-mass
spectrometry. Serum samples (1 ml) were supplemented with
deuterated oestrone (50 pg) and equilibrated overnight at
room temperature. Samples were soaked in Extrelut columns
(80 x 5 mm) and eluted with 7 ml dichloromethane. Residues
were purified by liquid chromatography on Sephadex LH-20
columns (120 x 4 mm) with n-hexane-ethanol-acetic acid
(80:20:1 v/v) as a first eluent (3 ml discarded), and n-hexane-
ethanol-acetic acid (70:30:1 v/v) as the second eluent; the
first 0.5 ml was discarded and oestrone was eluted in the next
3ml.
Oestrone was analysed by ID-MS of the TMS derivative
and ions M/Z 342 and 346 were quantified (Reiffsteck et al.,
1982). The sensitivities of the serum oestradiol and oestrone
assays were 10pmol 1' and 11 pmol I' respectively.
Serum SHBG was quantified using an 'in-house' saturation
analysis (Fattah & Chard, 1981). All other steroids (namely
oestradiol (Perry et al., 1987), androstenedione (A4) (Holly et
al., 1989), testosterone, (T) (Wathen et al., 1987), dihyd-
roepiandrostene sulphate (DHAS) (Wathen et al., 1987), pro-
gesterone (Wathen et al., 1984), cortisol (Cunnah et al., 1987)
and 1 1-deoxycortisol (Perry et al., 1982)) were measured by
radioimmunoassay (RIA) using 'in-house' methods. Serum
A4 and T were measured by RIA using a '25I-tracer after an
initial organic solvent extraction. The remaining assays also
employed '25I-tracer but did not require organic solvent ext-
raction or chromatographic purification.
The specificity of the RIA with reference to cross-reactivity
with 4-OHA is relevant. A personal communication (M.
Dowsett) has indicated that their serum oestrone RIA was
not showing the expected suppression by 4-OHA. Using the
serum oestrone method described above and performed by
Dr Dehenin it was apparent that a cross-reacting product
(suspected to be 4-OH-testosterone) could have been interfer-
ing in the serum oestrone RIA, which is why we used the
ID-MS method rather than try for a specific RIA technique.
There was no known cross-reaction of 4-OHA (<0.005%)
in the testosterone, progesterone, cortisol, 11-deoxycortisol,
DHAS and oestradiol assays; however we did observe a very
high cross-reaction (900%) in the androstenedione RIA,
which is why we have not presented that data.
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Table I Demographic and treatment details of patients entered
Previous
Years Subsequent response to
since Adjuvant therapy prior endocrine Sites of Response
Patient no. Age LMP Rx to this trial therapy disease to 4-OHA
1 75 20 T Yes S,N SD
2 46 - Oo T No B PD
3 66 14 T - - S SD
4 75 >20 T MPA, chemo No H,S PD
5 52 - Oo T Yes B,S PD
6 72 23 ICI, T Yes B PR
7 65 21 T Yes S PR
8 63 6 T - No N SD
9 76 >20 T Yes N PR
10 71 16 - T No N PD
11 74 >20 T T, D No B PR
12 57 5 T - No B PD
13 67 17 T Yes B PD
14 85 36 T MPA, chemo No N,L PD
15 60 8 T - No L w/d
16 70 22 MPA, T No S,N,B PR
17 56 22 T No L SD
18 47 - Oo No H PR
19 63 11 T No L PR
20 58 6 T No B w/d
T= tamoxifen. MPA=medroxyprogesterone acetate. chemo=mitrozantrone/cyclophosphamide. D = De-
cadurabolin. PR = partial response. SD = static disease. PD = progressive disease. w/d = withdrawn. Go =
oophorectomy. ICI = trial drug (ICI 118630). H = liver. N = nodel. L = lung. S = skin. B = bone.
When the serum SHBG levels were quantified, we had not
purified SHBG and could not therefore comment on the
potential binding of 4-OHA to SHBG. However, as a result
of the endocrine findings of this trial, we attempted and
succeeded in purifying SHBG (now the subject itself of a
publication) and this point is discussed further later.
Response
Clinical examination, biochemical, haematological and
radiological investigations were carried out at 0, 1, 2, 8 and
16 weeks or as indicated in addition. UICC criteria of re-
sponse were used, static disease (SD) was defined as no
change in the appearance ofmeasurable disease over a period
of at least 12 weeks. Any toxicity was noted. The trial period
was 16 weeks, those in remission beyond this time were
offered continued supplies of the drug and were reviewed
8-weekly.
Statistical methodology
For each variable of interest, paired t tests between each
pre-treatment and post-treatment values were performed. A
Bonferroni correction was applied to the significance levels so
obtained, in order to correct for multiple comparisons.
Results
Overall response rates
Twenty patients were entered into the study. Two patients
were not assessable: one patient was withdrawn from the
study after suddenly deciding to go abroad for 4 months (but
on returning to this country had static disease). The second
withdrawal occurred as the result of a side effect (see discus-
sion), leaving a total of 18 assessable patients. Seven of these
had responded to their first endocrine manoeuvre.
Seven of 18 (39%) achieved a partial response. Four
patients fulfilled the UICC criteria of static disease (SD).
Two of these actually showed slow disease progression,
which took 16 and 20 weeks respectively before an increase
of over 25% in the size of evaluable disease was recorded.
The remaining two showed a 'poor partial response', of less
than 50% reduction, progression occurred after 20 and 52
weeks. There were no complete responses (see Table I). The
mean duration of response was 8.2 months (range 3-13
months). Figure 1 illustrates a partial response.
There was no apparent correlation between site of disease
and response, nor between previous response to other endo-
crine therapy and response to 4-OHA. Indeed 4 of the 7
responses occurred in those who had not responded to other
hormonal therapies.
Endocrine results
Mean levels of DHAS, 170H progesterone, testosterone, pro-
gesterone and 11 deoxycortisol, expressed as a percentage of
pretreatment levels are shown in Figure 2. None of these
levels show any significant change during the course of the
study.
Levels of oestradiol (E2) and oestrone (El) are shown in
Figure 3. Both hormones fell significantly 2 weeks following
a single injection of 4-OHA: oestradiol from 26.6 pmol l-I to
15.37 pmol 1-' (a mean percentage suppression from 100% to
76%, P = 0.02), and oestrone from 196 pmol l- to
135 pmol 1 - (a mean percentage suppression from 100% to
64%, P = 0.012). After 8 and 16 weeks of fortnightly
therapy, levels had risen to 105% and 89% for oestradiol
and 110% and 86% for oestrone respectively.
Cortisol levels fell, from a pretreatment level of
490nmoll1' to a mean of 334nmoll1' after 2 weeks, then
rising to 370 nmol l-' after 8 weeks (Figure 3), the fall
between weeks 0 and 2 being highly significant (P = 0.0012).
Sex hormone binding globulin (SHBG) capacity gradually
fell from a pretreatment mean of 87 nmol 1-l to 45 nmol l-l
after 16 weeks (Figure 4). This fall was also statistically
significant (P = 0.03).
Assays of androstenedione showed variable results -
generally a rise. Earlier studies (Murray et al., 1988) had
suggested that this rise may have been due to precursor
block. As discussed previously, the results are unreliable due
to cross reaction.
Toxicity
A total of 11 episodes of transient soreness at the injection
site out of a total of 170 injections were reported by 5
patients. One withdrawal occurred in a woman who reported
a painful itchy lump near the injection site 4 days after the
second injection, and lasting for one week. When seen 3 days
later there were no abnormal findings nor residual symptoms4-HYDROXYANDROSTENEDIONE 311
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Figure 3 Levels of oestradiol, oestrone and cortisol after 2 and 8
weeks therapy, expressed as a percentage of pretreatment levels
(± I s.e. diff.). P values were calculated from paired t tests, and use
the Bonferroni correction for multiple comparisons.
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Figure 1 Bone scan before (left), and after 9 months of treatment
with 4-OHA (right).
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Figure 2 Levels of progesterone, 17-OH progesterone, testosterone,
DHAS, and 11 deoxycortisol expressed as a percentage of pretreat-
ment levels (± 1 s.e. diff.) after 2 and 8 weeks of therapy.
but she declined further treatment.
Three patients complained of transient malaise following
the injections, typically lasting a few days. Three patients
developed a transient maculo-papular rash, that was less
intense or widespread than the rash commonly seen with
aminoglutethimide.
One patient developed increased facial hair. She had been
on phenytoin for many years and had a small amount of
beard hair. There was a definite increase in the amount of
facial hair after 2 weeks, and this was maintained both whilst
on 4-OHA and subsequently. There were no other clinically
apparent androgenic side effects.
One patient developed dizziness, bronchospasm and
tachycardia a few minutes after her 19th injection. Recovery
was rapid and complete. This may have represented an
anaphylactic-type reaction or possibly rapid venous absorp-
tion of the drug. Rechallenge was considered unwise and the
drug was discontinued.
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Figure 4 Levels of SHBG during the course of the study. Weeks 16
vs week 0. P = 0.03, paired t test.
Discussion
Oestrogen deprivation appears to be an important
mechanism of endocrine therapy for breast cancer (Stoll,
1981). Most of the early work on 4-OHA has been carried
out by a single group of workers (Coombes et al., 1984,
1987a; Goss et al., 1986; Dowsett et al., 1987, 1989; Cun-
ningham et al., 1987; Brodie et al., 1987). They have reported
suppression of oestradiol levels to between 20 and 60 % of
pretreatment levels following oral or parenteral administra-
tion in a variety of doses. Earlier reports of an apparent lack
of effect on oestrone levels have now been shown to be due
to cross-reaction, levels of oestrone paralleling falls of oest-
radiol (Dowsett et al., 1989).
In this study we were able to confirm that both oestradiol
and oestrone levels were significantly reduced 2 weeks after a
single 250 mg injection of 4-OHA. However, as the study
progressed there was a rise in oestrogen levels to an average
of 93% of pretreatment levels. This fall is much less than
that reported by others.
Dosimetric studies (Dowsett et al., 1989) have shown that
a dose of 250 mg 2-weekly i.m. causes more variable suppres-
sion of oestradiol levels than 500 mg 2-weekly i.m. A
recovery phenomenon was observed with oestradiol levels
being significantly higher at 14 days than at 7 days. The
recovery phenomenon was particularly seen in those with
high (>35 pmol 1') pretreatment levels.
In our study, apart from at week 1, hormone levels were
only assessed after 14 days, just prior to the next injection. In
view of the clinical response rate observed, a possible ex-
Co
0)
0)
0)
E
40)
0)
0.
0
I a I I I
I312 T. PICKLES et al.
planation is that oestrogen suppression was maximal
between injections, recovery occurring before the next injec-
tion date. Levels at week 1 were not, however, lower than
those at week 2, which does not support this hypothesis.
Those with initially high oestradiol levels (>35 pmol 1',
n = 4) appeared to have more suppression than those with
lower initial levels, but this was not observed in those with
high oestrone levels (>260 pmol 1', n = 3). The plasma
concentration of 4-OHA following a single i.m. injection has
previously been shown to fall gradually over a period of 28
days (Coombes et al., 1987), with a half-life of 8 days
(Dowsett et al., 1984) suggesting that once fortnightly injec-
tions are sufficient. The long half-life is ascribed to the local
formation of a drug depot following deep i.m. injection
(Dowsett et al., 1989; data on file, Ciba Geigy). A dose of
250 mg i.m. fortnightly has previously been considered ade-
quate in suppressing oestradiol levels (Coombes et al., 1987),
It is not known to what level the (already very low) post-
menopausal levels of oestrogens need to be further supp-
ressed for clinical benefit. It is notable that despite a less than
dramatic percentage fall in El and E2 levels, 7/18 (39%) of
assessable patients achieved a partial response sustained for 8
months. It may be that tumour aromatase inhibition is more
relevant than plasma oestrogen suppression (Kouyoumdjian
et al., 1989; Hallam et al., 1989) and this aspect is currently
being investigated. We feel, however, that further dosimetric
studies should be carried out, as our data suggest that
4-OHA should be administered more frequently than 2-
weekly in view of the suboptimal oestradiol and oestrone
suppression.
SHBG reflects the oestrogen/androgen balance because the
synthesis of SHBG is stimulated by oestrogen and inhibited
by androgens. In postmenopausal women with very low oest-
rogen levels it is mainly a marker ofandrogenic activity. One
patient developed increased facial hair, which might have
been an androgenic side effect. However her SHBG level,
which was high initially, rose further (105 to 120 nmolI1).
We have found a significant late fall of SHBG, occurring
after 4 months on the drug from a mean of 87 to 45 nmol 1'
(Figure 4). A fall in SHBG has also been shown following
high dose oral treatment with 4-OHA (Dowsett et al., 1989),
and has been explained by the rapid and high levels of drug
presented to the liver - the site of SHBG synthesis, following
oral absorption. This has not been previously noted follow-
ing parenteral administration, even at higher dose, but the
data previously available refers only to 15 patients followed
for more than 1 month (Goss et al., 1986). Receptor studies
in animals have shown 4-OHA to have approximately 1% of
the androgenic activity of testosterone and androgenic
activity has been confirmed in rats (Brodie et al., 1977). We
have demonstrated that 4-OHA binds to SHBG with an
association constant (ka) of 2 X 10 M-I (unpublished data at
present). This implies that the drug does have weak an-
drogenic activity (cf. testosterone ka = 8 x 108 M-; DHT
ka = 10 X 108 M-I).
The nature of our SHBG assay, based on the competitive
binding of 3H-DHT to the binding protein is prone to poten-
tial interference. This potential interference can be due to the
drug or its metabolites, either of which could support the
possibility of the SHBG results being aberrantly low.
Three approaches can be taken to assess potential
interference: (a) serum from 4-OHA treated patients can be
treated with charcoal to remvoe potential interferants, but it
is a problematic procedure, (b) measure SHBG levels before
and after spiking with 4-OHA, however, this will not take
account of any interfering metabolites or (c) the use of an
immunoassay method for measurement of the SHBG protein
directly, which will be independent of steroid interference.
We took the last approach. SHBG levels were measured
using the Farmos SHBG-IRMA kit (Pharmacia cat.
no. 271001).
The Farmos SHBG-IRMA results were concordant with our
saturation SHBG assay (r =0.936; IRMA SHBG = 2.61 + 0.980
in house SHBG) confirming that our SHBG results were
unaffected by competition of endogenous steroids in the
patient samples.
DHAS, which acts as a marker of adrenal activity
remained unchanged during the study. Cortisol levels did
show an apparent fall between weeks 0 and 2, with subse-
quent improvement, but remained within the normal daytime
range. The fall in cortisol may have been due to initially high
stressed levels consequent upon the stress of the first out-
patient visit, a stress that reduced as familiarity increased. All
blood samples were taken between 10:00 and 12:00 - the
temporal changes in serum cortisol levels are not significantly
different during this time interval. There were no symptoms
of adrenal insufficiency.
A possible alternative explanation is that 4-OHA has a
direct effect upon adrenal steroidogenesis. This has not been
previously noted in either animal or human studies (Goss et
al., 1986; Coombes et al., 1984). However, although DHAS
has been reportedly unchanged in 11 patients (Goss et al.,
1986), cortisol levels were not reported in this trial. In one
trial ofonly 11 patients (Coombes et al., 1984), cortisol levels
were reportedly unchanged during the trial period. However,
three of these patients died within one month of treatment.
The effect of 4-OHA on cortisol levels is largely unknown
and further investigations are necessary.
Aminoglutethimide (AG) is the most widely used aroma-
tase inhibitor, but its main disadvantage is its toxicity. In our
experience AG is frequently (44%) associated with systemic
side effects such as rash (20%), lethargy and dizziness (9%).
These effects are more common in the elderly and therapy
has to be discontinued in 33% of those aged over 65 years
(Rowell et al., 1987). More serious toxicity such as fatal
agranulocytosis has occasionally been reported (Young et al.,
1984; Vincent et al., 1985). In addition, AG has effects upon
adrenal steroidogenesis, and should therefore be given with
hydrocortisone supplements to prevent adrenal insufficiency
(Murray & Pitt, 1985).
The side-effects that have been reported with 4-OHA in-
clude pain at the injection site, hot flushes, lethargy, rash,
rarely anaphylaxis, transient leucopenia and facial swelling
(Coombes et al., 1987). Our experience is similar, with one
patient refusing further treatment, possibly as a result of
developing a sterile abscess at the injection site, one possible
allergic reaction, and a further five patients developing tran-
sient soreness at the injection sites. The incidence of sympto-
matic sterile abscesses appears dose related, varying from
6.4% (this study) with 250 mg to 13% with 50 mg (Coombes
et al., 1987). Most patients develop an asymptomatic painless
subcutaneous lump which resolves over a few weeks.
Although oral 4-OHA has been used, with encouraging
clinical results, the parenteral route is currently favoured as
the oral preparations of the drug are still in the early stages
of development and evaluation. There appears to be marked
variation in enteral absorption and hepatic first-pass, leading
to a ten-fold difference in serum 4-OHA levels (Dowsett et
al., 1989).
Conclusion
Our results confirm the clinical effectiveness of 4-OHA. We
report a RR of 39% with a mean duration of response of 8
months. An encouraging finding, also noted previously is
that patients may respond to 4-OHA who have failed other
hormonal manoeuvres.
The drug is better tolerated than AG, the only established
aromatase inhibitor in clinical use. Its effect appears to be
mediated by oestradiol and oestrone suppression. Our
findings of a fall in SHBG level need to be further investi-
gated, as this may indicate androgenic activity not previously
reported with the drug.
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